$2.01
+0.01 (+0.25%)
Open$2.04
Previous Close$2.01
Day High$2.05
Day Low$1.97
52W High$2.66
52W Low$0.40
Volume—
Avg Volume826.6K
Market Cap268.48M
P/E Ratio—
EPS$-1.90
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,180.1% upside
Current
$2.01
$2.01
Target
$25.73
$25.73
$15.89
$25.73 avg
$34.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.10M | 17.71M | 19.64M |
| Net Income | 3.87M | 3.06M | 4.04M |
| Profit Margin | 21.4% | 17.3% | 20.6% |
| EBITDA | 5.83M | 6.29M | 6.55M |
| Free Cash Flow | 3.85M | 4.93M | 3.44M |
| Rev Growth | +0.2% | -1.6% | +10.4% |
| Debt/Equity | 0.48 | 0.65 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |